Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR22529-19] to Macrophage Inflammatory Protein 1 alpha / CCL3 - BSA and Azide free
  • Suitable for: Flow Cyt, ICC/IF, IP, WB
  • Reacts with: Human

Overview

  • Product name

    Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free
    See all Macrophage Inflammatory Protein 1 alpha / CCL3 primary antibodies

  • Description

    Rabbit monoclonal [EPR22529-19] to Macrophage Inflammatory Protein 1 alpha / CCL3 - BSA and Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: Flow Cyt, ICC/IF, IP, WBmore details
    Unsuitable for: IHC-P

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • IP: THP-1 (treated with PMA and LPS) whole cell lysate. ICC/IF: THP-1 (treated with PMA and LPS) cells. Flow cyt: THP-1 (treated with PMA and LPS) cells.

  • General notes

    Ab254289 is the carrier-free version of ab229900. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with

    ab254289 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Images

  • Immunoprecipitation - Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)
    Immunoprecipitation - Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)

    Macrophage Inflammatory Protein 1 alpha / CCL3 was immunoprecipitated from 0.35 mg of THP-1 (human monocytic leukemia cell line) (treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56h, followed by adding Lipopolysaccharide (1ug/ml) for a further 16h ) whole cell lysate with ab229900 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab229900 at 1/1000 dilution.

    VeriBlot for IP Detection Reagent (HRP) (ab131366), was used as secondary antibody at 1/5000 dilution.

    Lane 1: THP-1 (human monocytic leukemia cell line) (treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56h, followed by adding Lipopolysaccharide (1ug/ml) for a further 16h ) whole cell lysate 10 μg (Input).
    Lane 2: ab229900 IP in THP-1 (treated as above) whole lysate.
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab229900 in THP-1 (treated as above) whole cell lysate.

    Blocking and dilution buffer and concentration: NFDM/TBST.
    Exposure time: 40 seconds.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab229900).

  • Flow Cytometry - Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)
    Flow Cytometry - Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)

    Flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol-permeabilized THP-1 (human monocytic leukemia cell line) (untreated, green) / (treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56h, followed by adding Lipopolysaccharide (1ug/ml) for a further 16h, red) cells labeling Macrophage Inflammatory Protein 1 alpha / CCL3 with ab229900 at 1/500 dilution compared with a Rabbit monoclonal IgG Isotype control details (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG Fc (Alexa Fluor® 488) preadsorbed (ab150097), at 1/5000 dilution was used as the secondary antibody.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab229900).
  • Immunocytochemistry/ Immunofluorescence - Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)
    Immunocytochemistry/ Immunofluorescence - Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)

    Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized THP-1 (human monocytic leukemia cell line) cells labeling Macrophage Inflammatory Protein 1 alpha / CCL3 with ab229900 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining in THP-1 treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56 h, followed by adding Lipopolysaccharide (1ug/ml) for a further 16 h. The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) at 1/200 dilution (red).

    Secondary antibody only control: Used PBS instead of primary antibody, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.

    Treated: Cells treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56 h, followed by adding Lipopolysaccharide
    (1ug/ml) for a further 16 h.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab229900).

  • Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)
    Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 antibody [EPR22529-19] - BSA and Azide free (ab254289)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

© 2021 Astana Biomed Group LLP. All rights reserved.